Drugs affecting prelamin A processing: Effects on heterochromatin organization

Experimental Cell Research

Volumn 314, Issue 3, 2008, Pages 453-462

  Mattioli, Elisabetta ^a   Columbaro, Marta ^a   Capanni, Cristina ^a   Santi, Spartaco ^a   Maraldi, Nadir M ^a,b   D'Apice, M Rosaria ^c   Novelli, Giuseppe ^c   Riccio, Massimo ^d   Squarzoni, Stefano ^a   Foisner, Roland ^e   Lattanzi, Giovanna ^a  

^a CNR   (Italy)

^b RIZZOLI ORTHOPAEDIC INSTITUTE   (Italy)

^c UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^d UNIVERSITY OF ROME TOR VERGATA   (Italy)

^e MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

5 azadeoxycytidine; AFCMe; FTI 277; Heterochromatin organization; Prelamin A

Indexed keywords

ESTER DERIVATIVE; LAMIN A; N ACETYL S FARNESYL LEVO CYSTEINE METHYLESTER; N [[5 [(2 AMINO 3 MERCAPTOPROPYL)AMINO][1,1' BIPHENYL] 2 YL]CARBONYL]METHIONINE METHYL ESTER; PRELAMIN A; PROTEIN FARNESYLTRANSFERASE INHIBITOR; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; HETEROCHROMATIN; HISTOPATHOLOGY; HUMAN; HUMAN CELL; NORMAL HUMAN; PRIORITY JOURNAL; SKIN BIOPSY; WESTERN BLOTTING;

EID: 38349073319     PISSN: 00144827     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.yexcr.2007.11.012     Document Type: Article

References (34)

1. Lin E., and Worman H.J. Structural organization of the human gene encoding nuclear lamin A and nuclear lamin C. J. Biol. Chem. 268 (1993) 16321-16326
2. Sinensky M., Fantle K., and Dalton M. An antibody which specifically recognizes prelamin A but not mature lamin A: application to detection of blocks in farnesylation-dependent protein processing. Cancer Res. 54 (1994) 3229-3232
3. Corrigan D.P., Kuszczak D., Rusinol A.E., Thewke D.P., Hrycyna C.A., Michaelis S., and Sinensky M.S. Prelamin A endoproteolytic processing in vitro by recombinant Zmpste24. Biochem. J. 387 (2005) 129-138
4. Bergo M.O., Gavino B., Ross J., Schmidt W.K., Hong C., Kendall L.V., Mohr A., Meta M., Genant H., Jiang Y., Wisner E.R., van Bruggen N., Carano R.A.D., Michaelis S., Griffey S.M., and Young S.G. Zmpste24 deficiency in mice causes spontaneous bone fractures, muscle weakness, and a prelamin A processing defect. Proc. Natl. Acad. Sci. U. S. A. 99 (2002) 13049-13054
5. Rusinol A.E., and Sinensky M.S. Farnesylated lamins, progeroid syndromes and farnesyl transferase inhibitors. J. Cell Sci. 119 (2006) 3265-3272
6. Eriksson M., Brown W.T., Gordon L.B., Glynn M.W., Singer J., Scott L., Erdos M.R., Robbins C.M., Moses T.Y., Berglund P., Dutra A., Pak E., Durkin S., Csoka A.B., Boehnke M., Glover T.W., and Collins F.S. Recurrent de novo point mutations in lamin A cause Hutchinson-Gilford progeria syndrome. Nature 423 (2003) 293-298
7. Capanni C., Mattioli E., Columbaro M., Lucarelli E., Parnaik V.K., Novelli G., Wehnert M., Cenni V., Maraldi N.M., Squarzoni S., and Lattanzi G. Altered prelamin A processing is a common mechanism leading to lipodystrophy. Hum. Mol. Genet. 14 (2005) 1489-1502
8. Filesi I., Gullotta F., Lattanzi G., D'Apice M.R., Capanni C., Nardone A., Columbaro M., Scarano G., Mattioli E., Sabatelli P., Maraldi N.M., Biocca S., and Novelli G. Alterations of nuclear envelope and chromatin organization in mandibuloacral dysplasia, a rare form of laminopathy. Physiol. Genomics 23 (2005) 150-158
9. Navarro C.L., Cadinanos J., De Sandre-Giovannoli A., Bernard R., Courrier S., Boccaccio I., Boyer A., Kleijer W.J., Wagner A., Giuliano F., Beemer F.A., Freije J.M., Cau P., Hennekam R.C., Lopez-Otin C., Badens C., and Levy N. Loss of ZMPSTE24 (FACE-1) causes autosomal recessive restrictive dermopathy and accumulation of Lamin A precursors. Hum. Mol. Genet. 14 (2005) 1503-1513
10. Broers J.L.V., Ramaekers F.C.S., Bonne G., Yaou R.J., and Hutchison C.J. Nuclear lamins: laminopathies and their role in premature ageing. Physiol. Rev. 86 (2006) 967-1008
11. Mattout A., Dechat T., Adam S.A., Goldman R.D., and Gruenbaum Y. Nuclear lamins, diseases and aging. Curr. Opin. Cell Biol. 18 (2006) 1-7
12. Young S.G., Meta M., Yang S.H., and Fong L.G. Prelamin A farnesylation and progeroid syndromes. J. Biol. Chem. 281 (2006) 39741-39745
13. Glynn M.W., and Glover T.W. Incomplete processing of mutant lamin A in Hutchinson-Gilford progeria leads to nuclear abnormalities, which are reversed by farnesyltransferase inhibition. Hum. Mol. Genet. 14 (2005) 2959-2969
14. Fong L.G., Frost D., Meta M., Qiao X., Yang S.H., Coffinier C., and Young S.G. A protein farnesyltransferase inhibitor ameliorates disease in a mouse model of progeria. Science 311 (2006) 1621-1623
15. Columbaro M., Capanni C., Mattioli E., Novelli G., Parnaik V.K., Squarzoni S., Maraldi N.M., and Lattanzi G. Rescue of heterochromatin organization in Hutchinson-Gilford progeria by drug treatment. Cell. Mol. Life Sci. 62 (2005) 2669-2678
16. Shumaker D.K., Dechat T., Kohlmaier A., Adam S.A., Bozovsky M.R., Erdos M.R., Eriksson M., Goldman A.E., Khuon S., Collins F.S., Jenuwein T., and Goldman R.D. Mutant nuclear lamin A leads to progressive alterations of epigenetic control in premature aging. Proc. Natl. Acad. Sci. U. S. A. 103 (2006) 8703-8708
17. Scaffidi P., and Misteli T. Reversal of the cellular phenotype in the premature aging disease Hutchinson-Gilford progeria syndrome. Nat. Med. 11 (2005) 440-445
18. Adjei A.A., Davis J.N., Erlichman C., Svingen P.A., and Kaufmann S.H. Comparison of potential markers of farnesyltransferase inhibition. Clin. Cancer Res. 6 (2000) 2318-2325
19. Kilic F., Dalton M.B., Burrell S.K., Mayer J.P., Patterson S.D., and Sinensky M. In vitro assay and characterization of the farnesylation-dependent prelamin A endoprotease. J. Biol. Chem. 272 (1997) 5298-5304
20. Banaszynski L.A., Chen L.C., Maynard-Smith L.A., Ooi A.G., and Wandless T.J. A rapid, reversible, and tunable method to regulate protein function in living cells using synthetic small molecules. Cell 126 (2006) 995-1004
21. Haaf T., and Schmid M. Experimental condensation inhibition in constitutive and facultative heterochromatin of mammalian chromosomes. Cytogenet. Cell Genet. 91 (2000) 113-123
22. Remboutsika E., Lutz Y., Gansmuller A., Vonesch J.L., Losson R., and Chambon P. The putative nuclear receptor mediator TIF1alpha is tightly associated with euchromatin. J. Cell Sci. 112 (1999) 1671-1683
23. Kurg R., Tekkel H., Abroi A., and Ustav M. Characterization of the functional activities of the bovine papillomavirus type 1 E2 protein single-chain heterodimers. J. Virol. 80 (2006) 11218-11225
24. Pendas A.M., Zhou Z., Cadinanos J., Freije J.M., Wang J., Hultenby K.K., Astudillo A., Wernerson A., Rodriguez F., Tryggvason K., and Lopez-Otin C. Defective prelamin A processing and muscular and adipocyte alterations in Zmpste24 metalloproteinase-deficient mice. Nat. Genet. 31 (2002) 94-99
25. Gajewski A., Csaszar E., and Foisner R. A phosphorylation cluster in the chromatin-binding region regulates chromosome association of LAP2alpha. J. Biol. Chem. 279 (2004) 35813-35821
26. Dechat T., Korbei B., Vaughan O.A., Vlcek S., Hutchison C.J., and Foisner R. Lamina-associated polypeptide 2alpha binds intranuclear A-type lamins. J. Cell Sci. 113 (2000) 3473-3484
27. Lattanzi G., Columbaro M., Mattioli E., Cenni V., Camozzi D., Wehnert M., Santi S., Riccio M., Del Coco R., Maraldi N.M., Squarzoni S., Foisner R., and Capanni C. Pre-Lamin A processing is linked to heterochromatin organization. J. Cell. Biochem. 102 (2007) 1149-1159
28. Taylor M.R., Slavov D., Gajewski A., Vlcek S., Ku L., Fain P.R., Carniel E., Di Lenarda A., Sinagra G., Boucek M.M., Cavanaugh J., Graw S.L., Ruegg P., Feiger J., Zhu X., Ferguson D.A., Bristow M.R., Gotzmann J., Foisner R., and Mestroni L. Familial Cardiomyopathy Registry Research Group, Thymopoietin (lamina-associated polypeptide 2) gene mutation associated with dilated cardiomyopathy. Hum. Mutat. 26 (2005) 566-574
29. Bruzek L.M., Poynter J.N., Kaufmann S.H., and Adjei A.A. Characterization of a human carcinoma cell line selected for resistance to the farnesyl transferase inhibitor 4-(2-(4-(8-chloro-3,10-dibromo-6,11-dihydro-5H-benzo-(5,6)-cyclohepta(1,2-b)-pyridin-11(R)-yl)-1-piperidinyl)-2-oxo-ethyl)-1-piperidinecarboxamide (SCH66336). Mol. Pharmacol. 68 (2005) 477-486
30. Lerner E.C., Qian Y., Blaskovich M.A., Fossum R.D., Vogt A., Sun J., Cox A.D., Der C.J., Hamilton A.D., and Sebti S.M. Ras CAAX peptidomimetic FTI-277 selectively blocks oncogenic ras signaling by inducing cytoplasmic accumulation of inactive Ras-Raf complexes. J. Biol. Chem. 270 (1995) 26802-26806
31. Delarue F.L., Adnane J., Joshi B., Blaskovich M.A., Wang D.A., Hawker J., Bizouarn F., Ohkanda J., Zhu K., Hamilton A.D., Chellappan S., and Sebti S.M. Farnesyltransferase and geranylgeranyltransferase I inhibitors upregulate RhoB expression by HDAC1 dissociation, HAT association and histone acetylation of the RhoB promoter. Oncogene 26 (2007) 633-640
32. Unterberger A., Andrews S.D., Weaver I.C.G., and Szyf M. DNA methyltransferase 1 knockdown activates a replication stress checkpoint. Mol. Cell. Biol. (2006) 7575-7586
33. Goldman R.D., Shumaker D.K., Erdos M.R., Eriksson M., Goldman A.E., Gordon L.B., Gruenbaum Y., Khuon S., Mendez M., Varga R., and Collins F.S. Accumulation of mutant lamin A causes progressive changes in nuclear architecture in Hutchinson-Gilford progeria syndrome. Proc. Natl. Acad. Sci. U. S. A. 101 (2004) 8963-8968
34. Maraldi N.M., Squarzoni S., Sabatelli P., Capanni C., Mattioli E., Ognibene A., and Lattanzi G. Laminopathies: Involvement of structural nuclear proteins in the pathogenesis of an increasing number of human diseases. J. Cell. Physiol. 203 (2005) 319-327